Medicinal and edible composition for treating ulcerative colitis and application thereof
The treatment preparation for ulcerative colitis is prepared by the homologous composition of medicinal and food, including fried coix seed, fried locust rice, black plum, purslane, raw licorice and cinnamon, which solves the problem of major side effects of existing drugs and achieves the realization of It has effective treatment of low toxic side effects and easy to take effect, which is in line with the traditional characteristics of traditional Chinese medicine.
Patent Information
- Application Number
- CN202411337137.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-24
- Publication Date
- 2024-11-22
AI Technical Summary
The existing treatment drugs for ulcerative colitis have great side effects and are difficult to take for a long time, which affects the health of patients.
Use medicinal and food homologous compositions, including fried coix seed, fried locust rice, black plum, purslane, raw licorice and cinnamon, to prepare it into dry extract, granules or solid beverages, and it is concentrated under reduced pressure and freeze-dried. Then, we can form a therapeutic preparation that is easy to take.
This composition has low toxic side effects, is effective in treating ulcerative colitis, and is easy to take. It has a variety of practical values of prevention, health care and treatment. It conforms to the traditional characteristics of traditional Chinese medicine. The product is green and healthy, easy to carry and use.
Smart Images

Figure CN118987133A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to a medicine-food homologous composition for treating ulcerative colitis and application thereof. Background Art
[0002] Ulcerative colitis (UC) is a relatively common continuous inflammatory intestinal disease characterized by damage to the colorectal mucosa and submucosa, and will gradually spread to the entire colon and may damage the ileocecal area. Its causes include exposure to exogenous pathogens, improper diet, emotional disorders, spleen and stomach weakness, kidney yang deficiency, and blood stasis in the intestines. The disease has different properties such as cold, hot, deficiency, and excess; the main clinical manifestations are abdominal pain, diarrhea, mucus, pus, and blood in the stool, and tenesmus. The disease is prone to recurrence, and the course of the disease is long and difficult to cure. The drugs commonly used in the prior art have great side effects, and because they need to be taken for a long time, they seriously affect the health of UC patients.
[0003] There is an urgent need for a preparation with little toxicity and side effects and that can be taken for a long time to treat ulcerative colitis. Summary of the invention
[0004] The purpose of the present invention is to provide a medicine-food composition for treating ulcerative colitis and its application; the medicine-food composition can be prepared into granules or solid beverages, which can not only effectively treat ulcerative colitis, but also have little toxicity and side effects and can be taken for a long time.
[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0006] The invention provides a medicine-food composition for treating ulcerative colitis, comprising the following components in parts by weight: 4-8 parts of bran-fried coix seeds, 1-5 parts of fried sophora japonica seeds, 1-5 parts of black plums, 1-5 parts of purslane, 1-3 parts of raw licorice, and 0.5-1.5 parts of cinnamon.
[0007] The present invention also provides application of the medicine-food homologous composition in preparing a preparation for treating ulcerative colitis.
[0008] Preferably, the preparation is a dry extract, a granule or a solid beverage.
[0009] The present invention also provides a dry extract for treating ulcerative colitis, comprising the medicine-food homologous composition.
[0010] The present invention also provides a method for preparing the dry extract, comprising the following steps:
[0011] (1) mixing the edible and medicinal composition with water, soaking, boiling, filtering, and obtaining a medicinal solution;
[0012] (2) The medicinal solution is concentrated under reduced pressure and freeze-dried to obtain a dry extract.
[0013] Preferably, in step (1), the mass volume ratio of the edible and medicinal composition to water is 1 g: 15-25 mL;
[0014] The soaking time is 50 to 70 minutes;
[0015] The number of decoctions is 2 to 4 times, and the time of each decoction is 60 to 120 minutes;
[0016] In step (2), the temperature of the reduced pressure concentration is 50-60° C.;
[0017] The freeze drying includes precooling and freeze drying;
[0018] The precooling temperature is -70 to -90°C; the precooling time is 20 to 28 hours;
[0019] The freeze-drying temperature is -40 to -50°C; the freeze-drying time is 20 to 28 hours.
[0020] The present invention also provides a granule for treating ulcerative colitis, the granule comprising the following components: dry extract, mannitol and ethanol;
[0021] The dry extract is the dry extract.
[0022] The mass ratio of the dry extract to mannitol is 1:1-3;
[0023] The mass ratio of the dry extract to ethanol is 1:0.16-0.52;
[0024] The initial concentration of the ethanol is 75-85 wt %.
[0025] The present invention also provides a method for preparing the solid beverage, comprising the following steps:
[0026] The dry extract, mannitol and ethanol are mixed, granulated, and dried to obtain granules;
[0027] The drying temperature is 50-70°C; the drying time is 5-15 minutes;
[0028] The particle size of the particles is 10 to 65 meshes.
[0029] The present invention also provides a solid beverage for treating ulcerative colitis, comprising the following components in parts by weight: 40-52 parts of dry extract, 40-52 parts of auxiliary materials, 1-3 parts of stevioside, 4-8 parts of vitamin C, and 8-12 parts of ethanol;
[0030] The auxiliary materials include mannitol and maltodextrin; the mass ratio of mannitol to maltodextrin is 1-2:1-3;
[0031] The initial concentration of the ethanol is 75-85wt%;
[0032] The dry extract is the dry extract.
[0033] The present invention also provides a method for preparing the solid beverage, comprising the following steps:
[0034] The dry extract is mixed with auxiliary materials, stevioside, vitamin C and ethanol, granulated and dried to obtain a solid beverage;
[0035] The drying temperature is 50-70°C;
[0036] The particle size of the solid beverage is 10 to 80 meshes; the drying time is 5 to 15 minutes;
[0037] The water content of the solid beverage is 1-5%.
[0038] Beneficial effects of the present invention:
[0039] The invention is composed of six medicinal materials of ebony, purslane, sophora japonica seed, cinnamon bark, coix seed and liquorice, which are both medicinal and edible. Among them, ebony can restrain the lung, astringe the intestine and promote the production of body fluid, and treat the root of the disease by inhibiting wood and supporting soil. Purslane and sophora japonica seed can clear away heat and cool blood, detoxify and dry dampness, and the three medicines can be used together to remove rot and eliminate carbuncle, and eliminate pus and blood in stool, and they are the main medicine; cinnamon bark can dredge the meridians and remove blood stasis, warm and promote the flow of qi and blood to remove rot and promote the growth of flesh, and is conducive to the healing of ulcer surface, and can also control the bitter and cold nature of purslane and sophora japonica seed, and coix seed can strengthen the spleen and remove dampness, remove numbness and stop diarrhea, strengthen the spleen and invigorate qi and help transportation, and regulate qi mechanism, and they are the minister medicine; liquorice is used to coordinate the various medicines, and its sweet and slow nature is taken to treat abdominal pain and symptoms of urgent diarrhea caused by ulcerative colitis, relieve urgency and relieve pain, dispel cold and stop pain, and warm and dredge the meridians. Although the prescription is simple, it can replenish qi and spleen, clear liver and restrain lung, and the combination of hard and soft medicinal effects can achieve anti-inflammatory and analgesic effects. It is extremely consistent with the essence of the theory of "medicine and food are of the same origin" contained in traditional Chinese medicine since ancient times, and has multiple practical values such as prevention, health care and treatment. All aspects reflect the traditional characteristics of traditional Chinese medicine, among which "the medicine is extremely simple, the nature is the most peaceful, the taste is not bad, and it is easy to powder and take" and many other advantages make it widely popular.
[0040] The present invention also provides particles and solid beverages for treating ulcerative colitis. The above products are easy to brew, have uniform color after dissolution, have a strong and coordinated aroma, moderate sourness and sweetness, and are rich in nutrition. The solid beverage does not contain any preservatives and pigments, is a green and healthy product, is convenient to carry and use, is easily accepted by the general public, and has broad market prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 is the water absorption rate of the medicine-food composition;
[0042] Figure 2The effect of different decoction time on the dry extract yield;
[0043] Figure 3 The effect of different water addition amounts on the dry extract yield;
[0044] Figure 4 is the effect of different excipients on the solubility of particles;
[0045] Figure 5 is the effect of different drug-excipient ratios on the solubility of particles;
[0046] Figure 6 It is a granule for the treatment of ulcerative colitis;
[0047] Figure 7 It is the result of particle solubility experiment;
[0048] Figure 8 It is the thin layer identification of coix seed fried with bran;
[0049] Fig. 9 It is the thin layer identification of fried Sophora japonica rice;
[0050] Fig.10 It is the thin layer identification of ebony;
[0051] Fig.11 It is a thin layer identification of purslane;
[0052] Fig.12 It is the thin layer identification of raw licorice;
[0053] Fig.13 is the effect of particles on DAI scores in DSS-induced UC mice;
[0054] Fig.14 is the effect of particles on TNF-α, IL-6, IL-8, IL-17, and IL-10 in the serum of mice with DSS-induced UC (n=6);
[0055] Fig.15 is HE staining of mouse colon tissue (20× cross section);
[0056] Fig.16 It is the result of agarose gel electrophoresis;
[0057] Fig.17 It is the OTU distribution diagram, Figure A is the petal diagram, Figure B is the Venn diagram, where CON is the control group, DSS is the model group, and MXP is the particle group;
[0058] Fig.18 It is the analysis diagram of sample species composition, Figure A is at the phylum level, Figure B is at the genus level, where CON is the control group, DSS is the model group, and MXP is the particle group;
[0059] Fig.19 It is the Alpha diversity analysis chart, Figure A is the Rank-Abundance curve, Figure B is the Specaccum species accumulation curve, Figure C is the Chao index, and Figure D is the Shannon index, where CON is the control group, DSS is the model group, and MXP is the particle group;
[0060] Fig. 20 is the PCA analysis graph, where CON is the control group, DSS is the model group, and MXP is the particle group;
[0061] Fig.21 It is the LEfSe analysis diagram of intestinal flora in different groups, where DSS is the model group and MXP is the particle group;
[0062] Fig. 22 It is the PICRUSt functional prediction analysis diagram, where CON is the control group, DSS is the model group, and MXP is the particle group;
[0063] Fig.23 It is a solid drink for the treatment of ulcerative colitis;
[0064] Fig.24 It is the solubility test result of solid beverage. DETAILED DESCRIPTION
[0065] The present invention provides a medicine-food combination for treating ulcerative colitis, comprising the following components in parts by weight:
[0066] 4-8 parts of coix seeds fried with bran, preferably 6 parts; 1-5 parts of fried sophora japonica beans, preferably 3 parts; 1-5 parts of black plums, preferably 3 parts; 1-5 parts of purslane, preferably 3 parts; 1-3 parts of raw licorice, preferably 2 parts; 0.5-1.5 parts of cinnamon, preferably 1 part.
[0067] The present invention also provides application of the medicine-food homologous composition in preparing a preparation for treating ulcerative colitis.
[0068] In the present invention, the preparation is a granule or a solid beverage.
[0069] The present invention also provides a dry extract for treating ulcerative colitis, comprising the medicine-food homologous composition.
[0070] The present invention also provides a method for preparing the dry extract, comprising the following steps:
[0071] (1) mixing the edible and medicinal composition with water, soaking, boiling, filtering, and obtaining a medicinal solution;
[0072] (2) The medicinal solution is concentrated under reduced pressure and freeze-dried to obtain a dry extract.
[0073] In the present invention, in step (1), the mass volume ratio of the medicine-food composition and water is 1 g:15-25 mL, preferably 1 g:20 mL;
[0074] The soaking time is 50 to 70 minutes, preferably 55 to 65 minutes, and more preferably 60 minutes;
[0075] The decoction is performed 2 to 4 times, preferably 3 times; the decoction time for each decoction is 60 to 120 minutes, preferably 80 to 100 minutes, and more preferably 90 minutes;
[0076] In step (2), the temperature of the reduced pressure concentration is 50-60°C, preferably 53-57°C, and more preferably 55°C;
[0077] The freeze drying includes precooling and freeze drying;
[0078] The precooling temperature is -70 to -90°C, preferably -75 to -85°C, and more preferably -80°C; the precooling time is 20 to 28 hours, preferably 23 to 25 hours, and more preferably 24 hours;
[0079] The freeze-drying temperature is -40 to -50°C, preferably -43 to -47°C, and more preferably -45°C; the freeze-drying time is 20 to 28 hours, preferably 23 to 25 hours, and more preferably 24 hours.
[0080] The present invention also provides a granule for treating ulcerative colitis, the granule comprising the following components: dry extract, mannitol and ethanol;
[0081] The dry extract is the medicine-food homologous composition;
[0082] The mass ratio of the dry extract to mannitol is 1:1 to 3, preferably 1:2;
[0083] The mass ratio of the dry extract to ethanol is 1:0.16-0.52, preferably 0.26-0.42, and more preferably 0.34;
[0084] The initial concentration of the ethanol is 75-85 wt %, preferably 80 wt %.
[0085] The present invention also provides a method for preparing the particles, comprising the following steps:
[0086] The dry extract is mixed with mannitol and ethanol to prepare granules, and then dried to obtain granules;
[0087] The drying temperature is 50-70°C, preferably 55-65°C, and more preferably 60°C; the drying time is 5-15 minutes, preferably 8-12 minutes, and more preferably 10 minutes;
[0088] The particle size of the particles is 10 to 65 meshes, preferably 30 to 45 meshes, and more preferably 37.5 meshes.
[0089] The present invention also provides a solid beverage for treating ulcerative colitis, comprising the following components in parts by weight:
[0090] 40 to 52 parts of dry extract, preferably 42 to 50 parts, more preferably 46 parts;
[0091] 40 to 52 parts of auxiliary materials, preferably 42 to 50 parts, more preferably 46 parts;
[0092] 1 to 3 parts of stevioside, preferably 2 parts;
[0093] 4 to 8 parts of vitamin C, preferably 5 to 7 parts, more preferably 6 parts;
[0094] 8 to 12 parts of ethanol, preferably 9 to 11 parts, preferably 10 parts;
[0095] The auxiliary materials include mannitol and maltodextrin; the mass ratio of mannitol to maltodextrin is 1-2:1-3, preferably 1:2;
[0096] The initial concentration of ethanol is 75-85wt%, preferably 80wt%;
[0097] The dry extract is the medicine-food composition.
[0098] The present invention also provides a method for preparing the solid beverage, comprising the following steps:
[0099] The dry extract is mixed with auxiliary materials, stevioside, vitamin C and ethanol, granulated and dried to obtain a solid beverage;
[0100] The drying temperature is 50-70°C, preferably 55-65°C, and more preferably 60°C; the drying time is 5-15 minutes, preferably 8-12 minutes, and more preferably 10 minutes;
[0101] The particle size of the solid beverage is 10 to 80 meshes, preferably 40 to 50 meshes, and more preferably 45 meshes.
[0102] The water content of the solid beverage is 1-5%, preferably 2-4%, preferably 3%.
[0103] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0104] Example 1 A medicinal and edible composition for treating ulcerative colitis
[0105] 6g of coix seed fried with bran, 3g of sophora japonica seed, 3g of black plum, 3g of purslane, 2g of raw licorice, and 1g of cinnamon.
[0106] Example 2 A medicinal and edible composition for treating ulcerative colitis
[0107] 4g of coix seed fried with bran, 4g of sophora japonica seed, 2g of black plum, 4g of purslane, 1g of raw licorice, and 0.5g of cinnamon.
[0108] Example 3 A medicinal and edible composition for treating ulcerative colitis
[0109] 8g of coix seed fried with bran, 1g of sophora japonica seed, 4g of black plum, 2g of purslane, 3g of raw licorice, and 1.5g of cinnamon.
[0110] Example 4
[0111] The edible and medicinal composition of Example 1 was placed in a beaker, weighed, and 400 mL of distilled water was added. The water was drained and weighed every 10 minutes. The operation was repeated for 80 minutes. Four groups of experiments were performed in parallel. The water absorption of the edible and medicinal composition was recorded, and the water absorption rate of the edible and medicinal composition was calculated. The results are as follows: Figure 1 As shown;
[0112]
[0113] from Figure 1 It can be seen that the water absorption rate of Chinese medicinal materials tends to remain unchanged within 60 to 80 minutes.
[0114] Example 5 A dry extract for treating ulcerative colitis
[0115] Take the edible and medicinal composition of Example 1, add distilled water 10 times the mass of the edible and medicinal composition, soak for 60 minutes, decoct for 30 minutes, 60 minutes, 90 minutes and 120 minutes respectively, filter through 16 layers of filter cloth to obtain a medicinal solution, concentrate the medicinal solution under reduced pressure at 60°C in a rotary evaporator, precool at -80°C for 24 hours, and then freeze-dry at -45°C in a freeze dryer for 24 hours to obtain a dry extract, and calculate the extract yield of the dry extract. The results are as follows: Figure 2 As shown;
[0116]
[0117] from Figure 2It can be seen that the paste yield rate is highest when the boiling time is 90 minutes, and the paste yield rate is lowest when the boiling time is 30 minutes.
[0118] Example 6 A dry extract for treating ulcerative colitis
[0119] Take the medicine-food composition of Example 1, add 10 times, 15 times, 20 times, and 25 times of water respectively, soak for 60 minutes, decoct for 90 minutes, filter through 16 layers of filter cloth to obtain a medicinal solution, and concentrate the medicinal solution under reduced pressure at 60°C in a rotary evaporator, then precool at -80°C for 24 hours, and then freeze-dry at -45°C in a freeze dryer for 24 hours to obtain a dry extract. The extract yield of the dry extract was calculated. The results are as follows: Figure 3 shown.
[0120] from Figure 3 It can be seen that the paste yield obtained by using 10 times the amount of water is the lowest, while the paste yields obtained by using 15 times, 20 times, and 30 times the amount of water are the same.
[0121] Example 7 A granule for treating ulcerative colitis
[0122] The dry extract of Example 6 (15 times water is added) is mixed with starch, sucrose, sodium carboxymethyl cellulose (CMC-Na), dextrin, and mannitol in a ratio of 1:2, and 80% ethanol is added (dry extract: ethanol = 1:0.34), granulated, and dried in a drying oven at 60°C to obtain granules with a particle size of 50 mesh;
[0123] The forming rate of the particles was investigated, and the results are shown in Table 1.
[0124] Table 1 Particle Forming Rate
[0125] starch sucrose CMC-Na dextrin Mannitol Forming rate (%) 84.59 86.79 91.55 71.84 96.84
[0126] As can be seen from Table 1, the granule forming rate using mannitol as an auxiliary material is the highest, reaching 96.84%.
[0127] The solubility of the particles was tested as follows: the particles were ground into fine powder, 1.0 g of the fine powder was weighed, 50 mL of hot water was added, and the dissolution was observed for 30 minutes. The results were as follows: Figure 4 shown.
[0128] from Figure 4 It can be seen that the dissolution of mannitol as an excipient is basically soluble, and the dissolution of other excipients is relatively turbid.
[0129] Example 8 A granule for treating ulcerative colitis
[0130] The dry extract of Example 6 (15 times water was added) was mixed with mannitol at a ratio of 1:1, 1:2, 1:3, 1:4, and 1:5, and 80% ethanol was added (dry extract: ethanol = 1:0.34), granulated, and dried in a drying oven at 60° C. to obtain granules with a particle size of 50 mesh;
[0131] The forming rate and solubility of the particles were investigated with reference to Example 7. The results are shown in Tables 2 and Figure 5 As shown, mannitol 1 is in a ratio of 1:1, mannitol 2 is in a ratio of 1:2, and mannitol 3 is in a ratio of 1:3.
[0132] Table 2 Particle Formation Rate and Solubility
[0133] 1:1 1:2 1:3 1:4 1:5 Forming rate (%) 86.30 96.84 90.02 74.59 57.15 Solubility Slightly soluble Dissolve Basic dissolution / /
[0134] It can be seen from Table 2 that in the preparation process of granules, the molding rate and solubility of the drug-excipient ratio (dry extract: mannitol) of 1:2 are the best.
[0135] Experimental Example 1 Quality Inspection
[0136] 1.1 Observe Example 8 to prepare the granules (dry extract: mannitol = 1:2), such as Figure 6 shown.
[0137] from Figure 6 It can be seen that the particles are dry, without moisture absorption or agglomeration, and have a consistent appearance, color, and uniform size.
[0138] 1.2 Solubility of particles
[0139] Weigh 1.0 g of the granules (dry extract: mannitol = 1:2) prepared in Example 8, place it in a beaker, add 50 mL of hot water, stir for 5 min, and obtain a granule solution. Perform three sets of parallel tests. The results are as follows: Figure 7 shown.
[0140] from Figure 7 It can be seen that the particles are basically dissolved.
[0141] 1.3 Particle size
[0142] Weigh 20.0 g of the granules (dry extract: mannitol = 1:2) prepared in Example 8 and pass through No. 1 sieve (65 mesh) and No. 5 sieve (10 mesh). The granules that cannot pass through No. 1 sieve and the powder that can pass through No. 5 sieve cannot exceed 15%, which is qualified. Three sets of parallel experiments are performed, and the results are shown in Table 3.
[0143] Table 3 Particle size
[0144] 1 2 3 Unqualified amount / g 0.8245 0.8257 0.8213 Particle size qualified rate / % 95.88 95.87 95.89
[0145] As can be seen from Table 3, the particles are qualified.
[0146] 1.4 Particle size
[0147] The particle size of the particle solution prepared in 1.2 was measured using a Malvern instrument and the data were recorded, as shown in Table 4.
[0148] Table 4 Particle size, pdI value (x±s, n=3)
[0149]
[0150]
[0151] It can be seen from Table 4 that the measured particle size decreases when the particles are diluted 5 times, and the particle size gradually increases with the increase of the dilution multiple; the pdI value (polymer dispersibility index) decreases with the increase of the dilution multiple, and then gradually stabilizes at around 0.40.
[0152] 1.5 Thin layer identification of coix seed
[0153] Weigh 1.0 g of the granules (dry extract: mannitol = 1:2) prepared in Example 8, place it in a 50 mL conical flask 1, add 10 mL of petroleum ether (80 ° C), ultrasonically treat for 30 min, filter, spin-dry the filtrate, add 5 mL of petroleum ether, and obtain test solution 1; crush coix seed, weigh 1.0 g of coix seed powder, place it in a 50 mL conical flask 2, and operate in the same way to prepare test solution 2. Absorb test solution 1 and test solution 2 and spot them on the same silica gel G thin layer plate, the developing agent is petroleum ether (80 ° C): ethyl acetate: acetic acid (10:3:0.1). After development is complete, take it out, dry it, and inspect it under ultraviolet light at a wavelength of 365 nm. Figure 8 shown.
[0154] from Figure 8 It can be seen that the spot of test solution 1 and the spot of test solution 2 show fluorescence at the same position.
[0155] 1.6 Thin layer identification of Sophora japonica
[0156] Weigh 1.0 g of the granules (dry extract: mannitol = 1:2) prepared in Example 8, place it in a 10 mL test tube, add 5 mL of methanol, seal it and shake it for 10 min, filter, and take the filtrate to obtain test solution 3; accurately weigh 0.45 mg of rutin reference substance, add methanol to prepare a rutin reference substance solution with a concentration of 0.15 mg / mL, and obtain test solution 4; operate in the same way to prepare a quercetin reference substance solution to obtain test solution 5; absorb test solution 3 and test solution 4 and test solution 5 and spot them on two silica gel G thin layer plates, respectively, use water-formic acid-ethyl acetate in a ratio of 1:1:8 as the developing agent, and use aluminum chloride test solution as the color developer. After fully developing, take it out, dry it, spray aluminum chloride test solution evenly, and place it under ultraviolet light (365 nm) for inspection. Fig. 9 shown.
[0157] from Fig. 9 It can be seen that in the chromatogram of test solution 3, spots and fluorescence of the same color appear at the corresponding positions of the chromatograms of test solutions 4 and 5.
[0158] 1.7 Thin-layer identification of black plum
[0159] Weigh 1.0 g of the granules (dry extract: mannitol = 1:2) prepared in Example 8, place in a 50 mL conical flask, add 30 mL of methanol, and filter after ultrasonic treatment for 30 min. Discard the solid residue, spin-dry the filtrate, add 20 mL of water to the residue to dissolve it, pour it into a 60 mL separatory funnel, add tetrahydrofuran and shake to extract 2 times, 20 mL each time, combine the tetrahydrofuran solution, spin-dry it, soak the residue with 15 mL of petroleum ether (80 ° C) 2 times, then pour out the petroleum ether, add 2 mL of anhydrous ethanol was used to dissolve the residue as test solution 6; 1 g of black plum reference medicinal material was weighed and a reference medicinal material solution was prepared in the same manner to obtain test solution 7; test solution 6 and test solution 7 were respectively spotted on the same silica gel G thin layer plate, cyclohexane-ethyl acetate-dichloromethane-formic acid in a ratio of 20:8:5:0.1 was used as the developing agent, and 10% ethanolic sulfuric acid solution was used as the color developer. After the development was complete, the plate was taken out, dried, sprayed with an appropriate amount of color developer, and heated in an oven at 105°C until the spots were clearly colored. Fig.10 shown.
[0160] from Fig.10 It can be seen that test solution 6 and test solution 7 should present spots of the same color at corresponding positions.
[0161] 1.8 Thin layer identification of purslane
[0162] Weigh 1.0 g of the granules (dry extract: mannitol = 1:2) prepared in Example 8, place in a 50 mL conical flask, add 20 mL of water, adjust the pH value to 3 with formic acid, cold soak for 3 h, filter, spin dry the filtrate, add 5 mL of water to dissolve the residue, and obtain test solution 8; weigh 1.0 g of purslane control medicinal material, and prepare a control medicinal material solution in the same way to obtain test solution 9; absorb test solution 8 and test solution 9 and spot them on the same silica gel G thin layer plate, use n-butanol: glacial acetic acid: water (4:1:1) as the developing agent, take it out after it is fully developed, dry it, spray it with a color developer 0.2% ninhydrin ethanol solution, and then adjust the oven to 110°C and heat it until the spots are clearly colored, as shown in FIG. Fig.11 shown.
[0163] from Fig.11 It can be seen that under daylight conditions, test solution 8 and test solution 9 show spots of the same color at corresponding positions.
[0164] 1.8 Thin layer chromatography identification of licorice
[0165] Weigh 1.0 g of the granules (dry extract: mannitol = 1:2) prepared in Example 8, place in a round-bottom flask, add 40 mL of tetrahydrofuran, heat and reflux for 60 min, filter while hot, discard the solution, add 30 mL of methanol to the residue, heat and reflux for 60 min, cool to room temperature, filter, spin-dry the filtrate, add 40 mL of water to the residue to dissolve it, place in a 100 mL separatory funnel, extract with n-butanol three times, 25 mL each time, combine the n-butanol solution, spin-dry it, add 5 mL of methanol to the residue, and obtain test solution 10; weigh 1.0 g of reference medicinal material licorice and perform the same operation. Prepare a reference medicinal material solution to obtain test solution 11, then accurately weigh an appropriate amount of liquiritin reference substance, add methanol to prepare a reference substance solution with a concentration of 0.15 mg / mL, to obtain test solution 12; absorb the prepared test solutions 10, 11 and 12 respectively onto the same silica gel G thin layer plate prepared with 1% sodium hydroxide solution, use ethyl acetate: water: formic acid: glacial acetic acid (15:2:1:1) as the developing agent, after the development is complete, take it out, dry it, spray it with a color developer 10% sulfuric acid ethanol solution, heat it in an oven at 105°C until the spots are clearly colored, and inspect it under ultraviolet light at a wavelength of 365nm. Fig.12 shown.
[0166] from Fig.12 It can be seen that in the chromatogram of test solution 10, spots of the same color appear at positions corresponding to the chromatograms of test solution 11 and test solution 12.
[0167] Experimental Example 2
[0168] 2.1 Mouse treatment
[0169] (1) Forty-eight SPF-grade male C57BL / 6 mice, 6-8 weeks old, with a body weight of (23±2 g), were purchased from Chengdu Dashuo Experimental Animal Co., Ltd. The animal license number is SCXK(Sichuan)2020-030. They were housed in the SPF-grade experimental animal center of the Shaanxi Provincial Co-constructed Collaborative Innovation Center for Industrialization of Traditional Chinese Medicine Resources (approval number: SYXK(Shaanxi)2017-004). The indoor environment was maintained with a 12-hour light-dark cycle, a temperature of 24±0.5°C, and a humidity of 53±1%.
[0170] (2) After 7 days of adaptive feeding, the mice were randomly divided into 6 groups of 8 mice each, namely the control group, the model group, the positive drug group (sulfasalazine enteric-coated tablet suspension, 125 mg / kg), and the low, medium, and high-dose granule groups (150 mg / kg, 300 mg / kg, 600 mg / kg). The mice in the control group were given pure water to drink, and the mice in the other groups were freely given 2.5% dextran sulfate sodium (DSS) to induce the UC model. The body weight of the mice was recorded from the first day of modeling. The low, medium, and high-dose granule groups and the positive drug group were given intragastric administration at a volume of 10 mL / kg simultaneously, and the control group and the model group were given intragastric administration of an equal volume of pure water once a day for 12 consecutive days. After the last administration, the mice were fasted but allowed to drink water for 12 hours.
[0171] 2.2 Disease activity index (DAI) score
[0172] During the experiment, the body weight, stool characteristics, and blood in the stool characteristics of the mice were observed and recorded daily, and scored according to the DAI scoring standard (Table 5); where DAI=(body weight loss score + stool characteristics score + blood in the stool condition score) / 3, and the results are as Fig.13 shown.
[0173] Table 5 DAI scoring table
[0174] Weight loss rate (%) Stool characteristics Occult blood / bloody stools score 0 normal normal 0 1~5 Loose In between 1 5~10 Loose Occult blood in stool 2 10~15 Loose stools Naked bloody stool 3 >15 diarrhea Naked bloody stool 4
[0175] The mice in the control group had normal food intake and water intake, were active and agile, had normal body weight changes, and had no symptoms of diarrhea or blood in the stool. After the start of modeling in the model group, food intake decreased, activity was slow, body weight decreased, hair color was dull, soft stools and diarrhea symptoms appeared, and severe cases had blood in the stool and died. The DAI score of the mice in the model group increased after drinking DSS, indicating that the mouse model was successfully established. After administration, the body weight of the mice in the positive drug group and each dose granule group decreased slowly, and the DAI score was below 1 point, indicating that the granule had a certain protective effect on UC mice.
[0176] 2.3 Serum inflammatory factors and pathological histological observations
[0177] After intraperitoneal injection of sodium pentobarbital anesthesia, blood was collected from the abdominal aorta and centrifuged at 3000 r / min for 10 min. The serum was collected and stored at -80°C. The ELISA kit was used to detect the content of IL-6, IL-8, IL-10, IL-17, and TNF-α. The measurement results are shown in Fig.14 As shown; 1 cm of the mouse colon segment was taken from each group of mice 5 cm away from the anus, fixed with 4% paraformaldehyde, sliced, and stained with hematoxylin-eosin (HE). The results are shown as follows Fig.15 shown.
[0178] from Fig.14 It can be seen that the levels of pro-inflammatory factors TNF-α, IL-6, IL-8 and IL-17 in the serum of mice in the model group were significantly higher than those in the control group (P<0.01); the level of anti-inflammatory factor IL-10 was lower than that in the control group; the levels of pro-inflammatory factors in the serum of mice in the low-, medium- and high-dose groups of sulfasalazine and granules were significantly lower than those in the model group (P<0.01); the level of anti-inflammatory factors in the high-dose group of granules was significantly increased;
[0179] from Fig.15 It can be seen that the colon tissue of the control group mice was intact, with obvious crypts and goblet cells, regular crypt edges and no inflammatory infiltration; the colon of the model group showed increased inflammatory cell infiltration, crypt atrophy, upward movement and deformation, and a decrease in goblet cells; after administration of the positive drug group and each dose group of the particles, the colon structure and crypt structure were restored to a certain extent, and the inflammatory cell infiltration was reduced, indicating that the particles can improve DSS-induced colon inflammation in UC mice and reduce colon tissue damage in UC mice.
[0180] 2.4 Intestinal flora detection
[0181] (1) The total DNA of the intestinal contents of mice (control group, model group and high-dose particle group, 5 replicates in each group) was extracted using the Stool DNA Kit. The quality of DNA extraction was tested by 1% agarose gel electrophoresis (detection parameters: gel concentration: 1%; voltage: 170 V; electrophoresis time: 30 min) and Nanodrop2000 (test results are shown in Table 1). Fig.1630 ng of the 16S rRNA gene V4-V5 variable region was used for PCR amplification (the PCR amplification system and procedure are shown in Tables 6-7), and the amplification primer sequences were 16S V4-V5 (515-909) GTGCCAGCMGCCGCGGTAA (SEQ ID NO: 1) and CCCCGYCAATTCMTTTRAGT (SEQ ID NO: 2); the PCR product was recovered by gel excision using the FastPure DNA gel recovery kit, purified using the FastPure Gel DNA Extraction Mini Kit, and quantified using QuantiFluorTM-ST, and mixed in corresponding proportions according to the sequencing amount requirements of each sample; after quantitative mixing of the PCR products, the library was constructed according to the VAHTSUniversal DNA Library Prep Kit for Illumina V3 kit; after the library construction was completed, the Illumina MiSeq platform was used for sequencing to obtain the Pair-End (PE) double-end sequence, and the amplicon library was constructed using Trimmomatic v0.36 and Pear The original data quality control (Trimmomatic) was performed by using the software QIIME v.1.8.0 (QIIME v.1.8.0) with a sliding window size of 50 bp, an average quality of 20, and a minimum retention sequence length of 120; Pear removed the sequence with N), and the double-end sequences after de-impurity were spliced using the software FLASH v1.20 and Pear v0.9.6 (the minimum overlap was set to 10 bp, and the mismatch rate was 0.1) (the splicing results are shown in Table 8), and the chimeras in the sequences were removed using the UCHIME method; the high-quality sequences generated by the above preprocessing (the distribution statistics of high-quality sequences are shown in Table 9) were clustered into operational taxonomic units (OTUs) at 97% similarity using the UPARSE clustering method in the software QIIME v.1.8.0; a total of 1716 OUTs were generated, and a total of 1689 OTUs were obtained after leveling. There were 131 OTUs between samples, and the distribution of OUTs is shown in the figure below. Fig.17 As shown;
[0182] Table 6 PCR amplification system
[0183] Reagent ingredients volume DNA samples X(30ng) ForwardPrimer(5uM) 1μL Reverse Primer (5uM) 1μL BSA (2 ng / μL) 3μL 2×TaqPlusMasterMix 12.5μL <![CDATA[ddH2O]]> 7.5-XμL Total 25μL
[0184] Table 7 PCR amplification program
[0185]
[0186] Table 8 Statistics of splicing results
[0187]
[0188]
[0189] Note: Raw tags are the results of fastq data splicing after filtering low-quality data, and clean tags are the results of further removing chimeras and short sequences from the splicing results.
[0190] Table 9. Statistics of high-quality sequence distribution
[0191] Length(bp) Sequences distribute reads 0-200 0 200-260 510 260-320 107 320-360 163 360-380 1123055 380-400 108 400-420 49 420-440 23 440-460 27 460-480 15 480-500 5 500-520 2 520-540 0 540-560 0 560-600 0
[0192] (2) The above OTU representative sequences were compared with the Silva (Release 128) 16S rRNA database, and the RDP (Ribosomal Database Project) classification algorithm was used for species comparison and annotation. The confidence threshold was 0.7 to obtain the taxonomic information of the OTU representative sequences, and the sample community composition was analyzed at each classification level, such as Fig.18 As shown; Based on the OTU clustering results, mothur software was used to perform Alpha diversity analysis of each sample (Rank-Abundance curve, Specaccum species accumulation curve, observed_species, Shannon index) (as shown Fig.19 As shown in), Beta diversity analysis (as shown in Fig. 20 ); perform LDAEffect Size (LEfSe) multi-level species difference discriminant analysis based on linear discriminant analysis (LDA) to find species with significant differences in abundance between groups, such as Fig.21 shown.
[0193] from Fig.18 It can be seen that they were identified to belong to 11 phyla and 130 genera.
[0194] At the phylum level, the main phyla in each group of samples were Phylum Bacteroidetes, Phylum Firmicutes, Phylum Proteobacteria, Phylum Verrucomicrobiota, Phylum Deferribacterota, Phylum Desulfobacterota, Phylum Actinobacteriota, Phylum Campilobacterota, Phylum Cyanobacteria, and Phylum Patescibacteria; the abundance of Firmicutes bacteria in the model group was upregulated, while that of Bacteroidetes bacteria was downregulated; compared with the model group, MXP reduced the abundance of Firmicutes to a certain extent and increased the abundance of Bacteroidetes.
[0195] The most abundant bacterial genera identified at the genus level were Ileibacterium, Alistipes (Another branch bacteria), Alloprevotella, Bacteroides, Lachnospiraceae_NK4A136_group, Dubosiella, Lactobacillus, Prevotellaceae_UCG-001, etc.; compared with the control group, the abundance of E. coli, Bacteroides, and Enterobacter in the model group was downregulated, and the abundance of Alistipes, Prevotellaceae_UCG-001, Odoribacter, and Parabacteroides was upregulated; after administration, the abundance of the above genera was adjusted back compared with the model group. This shows that E. coli, Alloprevotella, Bacteroides, Prevotellaceae, Odoribacter, and Parabacteroides are related to the therapeutic effect of particles on UC.
[0196] The Rank-abundance curve can be used to analyze species abundance and species evenness: in the horizontal direction, the abundance of species is reflected by the width of the curve. The higher the species abundance, the larger the range of the curve on the horizontal axis. The smoothness of the curve reflects the evenness of species in the sample. The flatter the curve, the more even the species distribution. The Specaccum species accumulation curve describes the increase in species as the sample size increases. It can be used to determine whether the sample size is sufficient and to estimate species richness. The Alpha diversity index can reflect the abundance and diversity of the microbial community. After sampling and analyzing the number of samples with the lowest sequence number, the Chao index reflecting the species richness and the Shannon index reflecting the community diversity are obtained.
[0197] From the Rank-abundance curve ( Fig.19 A) and Specaccum species accumulation curve ( Fig.19 B) It can be seen that with the increase of sequencing depth and sample size, most microorganisms can be sequenced, and the species richness no longer increases with the increase of sample size, indicating that the sequencing depth and sample size in this study can meet the analysis requirements; Fig.19 C and 19D, it can be seen that modeling treatment and drug intervention have an impact on the number of intestinal flora species, which can regulate the increase and decrease of the abundance of different flora and cause changes in the diversity level of flora species; Fig.19 D shows that modeling treatment can reduce the Shannon index to a certain extent, while particle treatment can restore the Shannon index, indicating that particles can improve the structure of intestinal flora and optimize its species diversity index.
[0198] Beta diversity analysis uses the evolutionary relationship and abundance information between sample sequences to calculate the distance between samples, reflecting whether there are significant differences in microbial communities between samples. PCA analysis (Principal Component Analysis) can reflect the differences and distances between samples by analyzing the composition of OTUs (97% similarity) of different samples. PCA uses variance decomposition to reflect the differences between multiple groups of data on a two-dimensional coordinate graph. Fig. 20 It can be seen that there are differences in the microbiota structure between the control group and the model group, while the particle group and the control group are close, indicating that the microbiota structure changed after DSS modeling, and the intestinal microbiota structure was restored to a certain extent after particle treatment.
[0199] LEfSe analysis can compare multiple groups and find species with significant differences in abundance between groups. Fig.21It can be seen that the abundance of Bacteroides, Turicibacter, Faecalibaculum, Bilophila, Ruminococcus_gauvreauii_group, Romboutsia and Frisingicoccus decreased after particle treatment, indicating that these 8 bacterial genera are related to the therapeutic effect of UC; the intestinal microecology of IBD patients is severely imbalanced, the diversity of symbiotic bacteria is reduced, especially the number of Firmicutes and Bacteroidetes changes, which leads to intestinal mucosal damage.
[0200] (3) Metagenomic prediction and analysis
[0201] PICRUSt software can predict the gene type and quantity of the community based on the OTUs obtained from 16S rRNA gene sequencing, and use the KEGG database to obtain KO, Pathway, EC and other information for annotation and functional analysis; PICRUSt software was used to map the sequencing OTUs of the three groups of samples (control group, model group and particle group) to the GreenGene database for prediction and analysis of bacterial community functions and metabolic pathways, such as Fig. 22 shown.
[0202] from Fig. 22 It can be seen that after DSS modeling, lipoic acid metabolism, TCA cycle, fatty acid biosynthesis, folic acid biosynthesis, vitamin B6 metabolism, C5-branched dicarboxylic acid metabolism and other functions were upregulated, and secondary bile acid synthesis, alanine, aspartic acid and glutamate metabolism, streptomycin biosynthesis and other functions were downregulated; the abundance of secondary bile acids (SBAs) biosynthesis function was upregulated after particle administration. BAs and short-chain fatty acids are two main types of bacterial metabolites in the colon; SBAs can activate FXR (Farnesoid X receptor) to inhibit bacterial overgrowth and translocation, thereby improving intestinal inflammation.
[0203] Example 9 A solid beverage for treating ulcerative colitis
[0204] 10.0 g of the dry extract of Example 6 (15 times of water is added), 10.0 g of auxiliary materials (the ratios of mannitol and maltodextrin are 1:1, 1:2, 1:3, 2:1, and 3:1, respectively), 0.4 g of stevioside, and 1.3 g of vitamin C are mixed evenly, 2.17 g of 80% ethanol is added, granulated by extrusion through a 20-mesh sieve, and dried in an oven at 60° C. to obtain a solid beverage;
[0205] According to the provisions of the 2020 edition of the "Chinese Pharmacopoeia" under the granule item, the amount of particles passing through the No. 1 sieve (10 mesh) but not through the No. 5 sieve (80 mesh) is determined, and the molding rate is calculated. The calculation results are shown in Table 10.
[0206] Table 10 Auxiliary material screening - molding rate
[0207]
[0208] According to Table 10, the granule forming rate of the auxiliary materials prepared with mannitol: maltodextrin = 1:3 is the highest, reaching 96.79%.
[0209] Example 10 A solid beverage for treating ulcerative colitis
[0210] 10.0 g of the dry extract of Example 6 (15 times of water is added), 10.0 g of auxiliary materials (mannitol: maltodextrin = 1:3), 0.4 g of stevioside, and 1.3 g of vitamin C are mixed evenly, and 2.17 g of 60%, 70%, 80%, and 90% ethanol are added respectively, and granulated by extrusion through a 20-mesh sieve, and dried in an oven at 60° C. to obtain a solid beverage;
[0211] The appearance of the particles at different ethanol concentrations was observed and the results are shown in Table 11.
[0212] Table 11 Granulation results of different concentrations of ethanol
[0213] Wetting Agents Particle appearance 60% ethanol Sticky and clumpy, difficult to granulate 70% ethanol The particles are too coarse and the hardness is too high 80% ethanol Particles are formed with appropriate coarseness and fineness 90% ethanol Ethanol evaporates quickly and is difficult to granulate
[0214] As can be seen from Table 11, the granulation properties of 60% ethanol and 90% ethanol are poor, and the granules made with 70% ethanol are hard and difficult to dissolve. When 80% ethanol is used as a wetting agent, the obtained soft material has moderate viscosity and good granulation properties.
[0215] Example 11 A solid beverage for treating ulcerative colitis
[0216] The dry extract of Example 6 (15 times water is added), auxiliary materials (mannitol: maltodextrin = 1:3), 0.4g of stevioside, and 1.3g of vitamin C are mixed evenly, and 2.17g of 80% ethanol is added respectively, and granulated by extrusion through a 20-mesh sieve, and dried in an oven at 60°C to obtain a solid beverage;
[0217] The added amounts of dry extract and excipients are 10g and 5g (1:0.5), 10g and 10g (1:1), 8g and 12g (1:1.5), and 5g and 10g (1:2), respectively.
[0218] The appearance of the solid beverages prepared with different ratios of main ingredients to auxiliary ingredients was observed. The results are shown in Table 12.
[0219] Table 12 Granulation results of different main material and auxiliary material addition ratios
[0220] Drug-excipient ratio Particle properties 1:0.5 The granulation effect is average, the color is uneven, and the hygroscopicity is average 1:1 Good granulation effect, uniform color, low hygroscopicity, not easy to absorb moisture 1:1.5 The granulation effect is good, the finished product is slightly white, the hygroscopicity is low, and it is not easy to absorb moisture 1:2 The granulation effect is good, the finished product is obviously white, has low hygroscopicity and is not easy to absorb moisture
[0221] According to Table 12, when the drug-excipient ratio increases, the hygroscopicity of the finished product decreases, the color uniformity improves, and it is easier to granulate. However, if the drug-excipient ratio is too large, the color of the finished product will be obviously white, and the content of the medicinal material itself will be low. When the drug-excipient ratio is 1:1, the finished product has uniform color and low hygroscopicity, which is conducive to processing and storage. Therefore, choosing a drug-excipient ratio of 1:1 for granulation is the best choice.
[0222] Example 12 A solid beverage for treating ulcerative colitis
[0223] 10.0 g of the dry extract of Example 6 (15 times of water is added), 10.0 g of auxiliary materials (mannitol: maltodextrin = 1:3), 1.3 g of vitamin C, 2.2 g of xylitol, 2.2 g of maltitol, 2.2 g of sorbitol, 0.9 g of steviol glycoside, 0.7 g of steviol glycoside, 0.4 g of steviol glycoside, and 0.2 g of steviol glycoside are mixed uniformly, 2.17 g of 80% ethanol is added respectively, granulated by extrusion through a 20-mesh sieve, and dried in an oven at 60° C. to obtain a solid beverage;
[0224] Take 2g of the obtained solid beverage, add it to 200mL of 80℃ drinking water, stir until fully dissolved, and then select 10 students to conduct a comprehensive evaluation of its quality according to the sensory evaluation standards for solid beverages listed in Table 13. The appearance (20 points), solution state (25 points), smell (25 points), and taste (30 points) of the solid beverage are examined and scored. The average value of the scores is taken as the final result. The results are shown in Table 14.
[0225] Table 13 Sensory evaluation standards for solid beverages
[0226]
[0227] Table 14 Sensory scores of granules prepared with different sweeteners
[0228] Sweeteners Addition amount / g Sensory Rating Xylitol 2.2 83.2 Maltitol 2.2 81.3 Sorbitol 2.2 82.4 Stevioside 0.9 89.5 Stevioside 0.7 90.4 Stevioside 0.4 96.2 Stevioside 0.2 95.7
[0229] According to Table 14, when the amount of sweeteners xylitol, maltitol, and sorbitol added was 2.2g, the sensory score was not high, there was obvious astringency, and the sweetness was insufficient. If too much sweetener was added, it would not only reduce the drug content, but also may affect the quality of solid beverages. However, when stevioside was selected, even if the amount added was small, the taste evaluation was higher than other sweeteners, which not only completely covered the bitter taste of the drug, but also provided excellent sweetness, so stevioside was regarded as the best choice of sweetener; through sensory evaluation, it was found that the highest score was obtained after adding 0.4g of stevioside, with a smooth taste, moderate sweetness, and no peculiar smell; stevioside was widely used in the field of sweeteners based on its high sweetness, low calories, high safety, good solubility and stability.
[0230] Example 13 A solid beverage for treating ulcerative colitis
[0231] 10.0 g of the dry extract of Example 6 (15 times of water is added), 10.0 g of auxiliary materials (mannitol: maltodextrin = 1:3), 0.4 g of steviol glycoside, 1.5 g of anhydrous citric acid, 1.5 g of L-malic acid, 1.5 g of DL-tartaric acid, 1.5 g of lactic acid, 1.5 g of vitamin C, 1.3 g of vitamin C, and 1.1 g of vitamin C are mixed uniformly, 2.17 g of 80% ethanol is added respectively, granulated by extrusion through a 20-mesh sieve, and dried in an oven at 60° C. to obtain a solid beverage;
[0232] The solid beverage was subjected to sensory evaluation according to the method described in Example 12. The evaluation results are shown in Table 15.
[0233] Table 15 Sensory scores of granules prepared with different acidulants
[0234] Acidulants Addition amount / g Sensory Rating Anhydrous citric acid 1.5 89.5 DL-Tartaric acid 1.5 82.3 L-Malic Acid Pure 1.5 84.5 lactic acid 1.5 86.2 Vitamin C 1.5 93.6 Vitamin C 1.3 96.7 Vitamin C 1.1 92.1
[0235] According to Table 15, the acidity of the solid beverage is high when 1.5g of acidulant is added, and the sensory score is the highest when 1.3g of vitamin C is added. Among the selected acidulants, lactic acid has a good antibacterial effect, but the taste is not harmonious. Anhydrous citric acid has a mellow and excellent sour taste, but it is retained for a short time after entering the mouth, and the taste is slightly thin when used alone; the product obtained after adding DL-tartaric acid has a heavier sour and astringent feeling, with a certain irritation, and it has almost no masking effect on the sour taste of the product itself; L-malic acid pure completely masks the characteristic flavor of the product due to its own smell, and has a certain irritation, and has no improvement effect on the astringency of the product itself; after the product is added with vitamin C, it masks the bitter taste of the product, and the flavor is harmonious and delicious. The product with 1.3g of vitamin C has the highest sensory score, moderate sweetness and sourness, excellent taste, and the best taste.
[0236] Experimental Example 3
[0237] 3.1 Particle appearance and properties inspection
[0238] Take 5g of the solid beverage described in Example 13 (such as Fig.23 As shown in the figure, spread it flat on a clean white porcelain plate and observe the appearance of the particles with the naked eye under natural light. The finished particles should be brown-yellow in color, uniform in size, and not easy to absorb moisture or agglomerate.
[0239] 3.2 Particle size inspection
[0240] Take 10 g of the solid beverage described in Example 13, pass it through No. 1 (10 mesh) and No. 5 medicine sieves (80 mesh), keep the medicine sieve in a horizontal state, move back and forth left and right, and tap while sieving for 3 minutes. The powder that can pass through the No. 5 sieve and the particles that cannot pass through the No. 1 sieve cannot exceed 15%. The total mass is weighed as the qualified weight, and the qualified rate is calculated. The results are shown in Table 16.
[0241] Table 16 Particle size inspection results
[0242] serial number 1 2 3 average value Unqualified amount / g 0.4664 0.4176 0.4227 0.4356 Particle size qualified rate / % 95.336 95.824 95.773 95.644
[0243] The powder that can pass through the No. 5 sieve and the particles that cannot pass through the No. 1 sieve cannot exceed 15%. As can be seen from Table 16, the particle size test results are qualified.
[0244] 3.3 Determination of moisture content
[0245] Referring to the 0832 moisture determination method in the general rules of the fourth volume of the 2020 edition of the "Chinese Pharmacopoeia", take an appropriate amount of Amaranthus and Mie composite solid beverage, spread it flat in a flat weighing bottle (dried to a certain weight), weigh it accurately, dry it in a 60°C oven for 5 hours, then cool it in a dryer for 30 minutes, weigh it accurately again, dry it at the above temperature for another 1 hour, weigh it after cooling, and the difference between the two weighings is less than 5 mg. Finally, calculate the moisture content, as shown in Table 17.
[0246]
[0247] Table 17 Moisture content determination results
[0248] serial number Mass / g Moisture content / % 1 1.043 1.12 2 1.024 1.09 3 1.031 1.10 average value 1.033 1.10
[0249] It can be seen from Table 17 that the water content inspection standard specified in the Pharmacopoeia is met.
[0250] 3.4 Solubility test
[0251] 1.3 g of the solid beverage described in Example 13 was poured into 150 mL of 80°C hot water and stirred for about 2 min. The dissolution state of the solid beverage was immediately observed. Three sets of parallel experiments were set up. The results were as follows: Fig.24shown.
[0252] It can be observed that the particles are completely dissolved without precipitation or suspension. The finished solution is yellow-brown in color and uniform, with no stratification, which has met the inspection standards for granular solid beverages.
[0253] It can be seen from the above embodiments that the present invention provides a medicine-food composition for treating ulcerative colitis and its application. The medicine-food composition can be prepared into granules or solid beverages, which can not only effectively treat ulcerative colitis, but also have little toxicity and side effects and can be taken for a long time.
[0254] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A medicinal and edible composition for treating ulcerative colitis, characterized in that: The invention comprises the following components in parts by weight: 4-8 parts of coix seeds fried with bran, 1-5 parts of fried sophora japonica seeds, 1-5 parts of black plums, 1-5 parts of purslane, 1-3 parts of raw licorice and 0.5-1.5 parts of cinnamon.
2. Use of the medicine-food composition according to claim 1 in preparing a preparation for treating ulcerative colitis.
3. The use according to claim 2, characterized in that: The preparation is a dry extract, a granule or a solid beverage.
4. A dry extract for treating ulcerative colitis, characterized in that: The invention comprises the medicine-food composition as claimed in claim 1.
5. The method for preparing the dry extract according to claim 4, characterized in that: The steps include: (1) mixing the edible and medicinal composition with water, soaking, boiling, filtering, and obtaining a medicinal solution; (2) The medicinal solution is concentrated under reduced pressure and freeze-dried to obtain a dry extract.
6. The dry extract according to claim 5, characterized in that In step (1), the mass volume ratio of the edible and medicinal composition to water is 1 g: 15-25 mL; The soaking time is 50 to 70 minutes; The number of decoctions is 2 to 4 times, and the time of each decoction is 60 to 120 minutes; In step (2), the temperature of the reduced pressure concentration is 50-60° C.; The freeze drying includes precooling and freeze drying; The precooling temperature is -70 to -90°C; the precooling time is 20 to 28 hours; The freeze-drying temperature is -40 to -50°C; the freeze-drying time is 20 to 28 hours.
7. A particle for treating ulcerative colitis, characterized in that: The granules include the following components: dry extract, mannitol and ethanol; The dry extract is the dry extract according to claim 4. The mass ratio of the dry extract to mannitol is 1:1-3; The mass ratio of the dry extract to ethanol is 1:0.16-0.52; The initial concentration of the ethanol is 75-85 wt %.
8. The method for preparing the particles according to claim 7, characterized in that: The steps include: The dry extract, mannitol and ethanol are mixed, granulated and dried to obtain granules; The drying temperature is 50-70°C; the drying time is 5-15 minutes; The particle size of the particles is 10 to 65 meshes.
9. A solid beverage for treating ulcerative colitis, characterized in that: The invention comprises the following components in parts by weight: 40 to 52 parts of dry extract, 40 to 52 parts of auxiliary materials, 1 to 3 parts of stevioside, 4 to 8 parts of vitamin C, and 8 to 12 parts of ethanol; The auxiliary materials include mannitol and maltodextrin; the mass ratio of mannitol to maltodextrin is 1-2:1-3; The initial concentration of the ethanol is 75-85wt%; The dry extract is the dry extract according to claim 4.
10. The method for preparing a solid beverage according to claim 9, characterized in that: The steps include: The dry extract is mixed with auxiliary materials, stevioside, vitamin C and ethanol, granulated and dried to obtain a solid beverage; The drying temperature is 50-70°C; the drying time is 5-15 minutes; The particle size of the solid beverage is 10 to 80 meshes; The water content of the solid beverage is 1-5%.
Citation Information
Patent Citations
Traditional Chinese medicine preparation for treating chronic colitis, capsule and preparation method thereof
CN105999165A
Composition for improving or treating radiation enteritis and preparation method and application thereof
CN107007671A
Traditional Chinese medicine granule for treating ulcerative colitis
CN108815495A
Traditional Chinese medicine composition for improving or treating radiation enteritis disease
CN118542919A
